Anti-cancer treatment through the CIP2A-PP2A-AKT cascade has more recently been demonstrated through the treatment of TKI resistant NSCLC with Cucurbitacin B, a plant based therapeutic [107]. Here, CIP2A is linked to non-small cell lung carcinoma.